Skip to main content
. 2021 May 15;11(5):2159–2173.

Figure 3.

Figure 3

miR-22 regulated T cell differentiation. A-D. Flow cytometry analysis of CD4 T cells, CD8 T cells, FoxP3 positive T cells and IL-17 positive T cells in tumors from lenti-ctrl or lenti-miR-22 treatment group (n=4). E. Expression of IFN-γ, IL-17, IL-4, IL-6 and TNF-α in Hepa1-6 tumors from lenti-ctrl or lenti-miR-22 treatment group (n=4). F. Expression of IFN-γ, IL-17, IL-4, IL-6 and TNF-α in primary liver tumors from lenti-ctrl or lenti-miR-22 treatment group (n=4). G. qPCR analysis of miR-22 expression in T cells that were infected with lenti-miR-22 or control group (n=3, P<0.0001). H. Flow cytometry analysis of IL-17 T positive cells that were infected with lenti-miR-22 or control group (n=4, P=0.0001). I. Determination of IL-17 expression in T cells that were infected with lenti-miR-22 or control group (n=3, P<0.0001).